Protagonist Net Working Capital vs Long Term Debt Total Analysis
PTGX Stock | USD 29.98 0.43 1.41% |
Protagonist Therapeutics financial indicator trend analysis is much more than just breaking down Protagonist Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Protagonist Therapeutics is a good investment. Please check the relationship between Protagonist Therapeutics Net Working Capital and its Long Term Debt Total accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagonist Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.
Net Working Capital vs Long Term Debt Total
Net Working Capital vs Long Term Debt Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Protagonist Therapeutics Net Working Capital account and Long Term Debt Total. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Protagonist Therapeutics' Net Working Capital and Long Term Debt Total is 0.56. Overlapping area represents the amount of variation of Net Working Capital that can explain the historical movement of Long Term Debt Total in the same time period over historical financial statements of Protagonist Therapeutics, assuming nothing else is changed. The correlation between historical values of Protagonist Therapeutics' Net Working Capital and Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Working Capital of Protagonist Therapeutics are associated (or correlated) with its Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt Total has no effect on the direction of Net Working Capital i.e., Protagonist Therapeutics' Net Working Capital and Long Term Debt Total go up and down completely randomly.
Correlation Coefficient | 0.56 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Net Working Capital
Long Term Debt Total
Most indicators from Protagonist Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Protagonist Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagonist Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.Enterprise Value is likely to rise to about 1.2 B in 2024, whereas Selling General Administrative is likely to drop slightly above 18 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 443K | 4.1M | 12.9M | 13.6M | Net Interest Income | 443K | 4.1M | 12.9M | 13.6M |
Protagonist Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Protagonist Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Protagonist Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 154.9M | 324.5M | 347.7M | 247.9M | 358.0M | 204.1M | |
Other Current Liab | (10.2M) | 21.2M | 38.6M | 25.0M | 19.4M | 13.5M | |
Total Current Liabilities | 35.4M | 40.2M | 44.0M | 31.2M | 21.3M | 27.7M | |
Total Stockholder Equity | (217.7M) | (283.8M) | (409.4M) | (536.8M) | 336.7M | 353.5M | |
Net Tangible Assets | 80.0M | 279.6M | 300.0M | 215.6M | 247.9M | 141.3M | |
Property Plant And Equipment Net | 7.7M | 6.4M | 6.7M | 4.6M | 2.1M | 3.4M | |
Net Debt | (16.0M) | (111.4M) | (117.8M) | (122.1M) | (185.6M) | (176.3M) | |
Retained Earnings | (217.7M) | (283.8M) | (409.4M) | (536.8M) | (615.7M) | (584.9M) | |
Accounts Payable | 2.8M | 3.1M | 1.6M | 3.6M | 772K | 733.4K | |
Cash | 33.0M | 117.4M | 123.7M | 125.7M | 186.7M | 196.1M | |
Non Current Assets Total | 9.6M | 8.9M | 7.0M | 10.6M | 2.4M | 2.3M | |
Other Assets | 450K | 1.1M | 1.9M | 225K | 258.8K | 245.8K | |
Cash And Short Term Investments | 133.0M | 307.8M | 326.9M | 237.4M | 341.6M | 191.4M | |
Net Receivables | 6.8M | 3.5M | 4.4M | 52K | 10.3M | 10.8M | |
Common Stock Shares Outstanding | 25.9M | 34.4M | 46.3M | 49.0M | 56.8M | 29.8M | |
Short Term Investments | 100.0M | 188.5M | 203.2M | 111.6M | 154.9M | 99.8M | |
Liabilities And Stockholders Equity | (142.7M) | (238.9M) | (361.7M) | 247.9M | 358.0M | 375.8M | |
Non Current Liabilities Total | 39.5M | 4.6M | 3.7M | 784.7M | 221K | 210.0K | |
Inventory | 4.8M | 4.0M | 8.5M | (94K) | (10.3M) | (9.8M) | |
Other Current Assets | 744K | 311K | 975K | 42K | 14.0M | 14.7M | |
Other Stockholder Equity | 221K | (28K) | 299K | 359K | 952.5M | 1.0B | |
Total Liab | 75.0M | 44.9M | 47.7M | 784.7M | 21.3M | 20.2M | |
Property Plant And Equipment Gross | 7.7M | 6.4M | 11.0M | 9.9M | 8.4M | 5.1M | |
Total Current Assets | 145.3M | 315.6M | 340.7M | 237.4M | 355.6M | 196.9M | |
Accumulated Other Comprehensive Income | (221K) | 28K | (299K) | (359K) | (105K) | (110.3K) | |
Property Plant Equipment | 7.7M | 1.5M | 6.7M | 1.6M | 1.8M | 2.5M | |
Capital Surpluse | 297.8M | 563.4M | 709.7M | 752.7M | 865.6M | 908.9M | |
Retained Earnings Total Equity | (217.7M) | (283.8M) | (409.4M) | (536.8M) | (483.1M) | (458.9M) | |
Current Deferred Revenue | 41.5M | 14.5M | 1.6M | 69K | 3K | 2.9K | |
Net Invested Capital | 89.8M | 279.6M | 300.0M | 215.6M | 336.7M | 228.6M | |
Net Working Capital | 109.9M | 275.4M | 296.7M | 211.9M | 334.3M | 227.5M | |
Short Term Debt | 1.3M | 1.5M | 2.2M | 2.5M | 1.1M | 1.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Protagonist Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protagonist Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protagonist Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protagonist Therapeutics Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagonist Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.Note that the Protagonist Therapeutics information on this page should be used as a complementary analysis to other Protagonist Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Protagonist Stock analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.
CEOs Directory Screen CEOs from public companies around the world | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Fundamental Analysis View fundamental data based on most recent published financial statements |
Is Protagonist Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagonist Therapeutics. If investors know Protagonist will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagonist Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 2.54 | Revenue Per Share 5.308 | Quarterly Revenue Growth (1.00) | Return On Assets 0.2138 | Return On Equity 0.4175 |
The market value of Protagonist Therapeutics is measured differently than its book value, which is the value of Protagonist that is recorded on the company's balance sheet. Investors also form their own opinion of Protagonist Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagonist Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagonist Therapeutics' market value can be influenced by many factors that don't directly affect Protagonist Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagonist Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagonist Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagonist Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.